TAO Synergies (TAOX) Net Cash Flow (2019 - 2026)
TAO Synergies' (TAOX) quarterly Net Cash Flow came in at -$1.3 million in Q2 2026, down 131.65% on a YoY basis from $4.0 million in Q2 2025, and up 31.02% quarter-over-quarter from -$1.9 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Net Cash Flow (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Net Cash Flow for 8 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Cash Flow fell 131.65% year-over-year to -$1.3 million; the trailing twelve-month figure through Jun 2026 stood at -$12.0 million (down 571.55% YoY), and the FY2025 full-year result was -$12.2 million, down 10.48% from the prior year.
- Net Cash Flow improved to -$1.3 million in Q2 2026 per TAOX's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $11.1 million in Q4 2022 and bottomed at -$12.9 million in Q3 2025.
- Historically, Net Cash Flow has averaged -$1.2 million across 5 years, with a median of -$1.8 million in 2023.
- The widest YoY moves for Net Cash Flow: up 398.22% in 2025, down 1153.51% in 2025.
- Over 5 years, Net Cash Flow stood at $11.1 million in 2022, then slumped by 127.51% to -$3.1 million in 2023, then soared by 35.76% to -$2.0 million in 2024, then jumped by 305.74% to $4.1 million in 2025, then sank by 131.52% to -$1.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.3 million, -$1.9 million, and $4.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -170.75 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -1.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 Mn |
| Mar 31, 2026 | -1.85 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Sep 30, 2025 | -12.92 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | -2.82 Mn |
| Dec 31, 2024 | -1.97 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Mar 31, 2024 | -2.33 Mn |
| Dec 31, 2023 | -3.07 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -2.52 Mn |
| Mar 31, 2022 | -2.93 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | -407,441.00 |